Johnson & Johnson (NYSE:JNJ) Shares Bought by Arlington Partners LLC

Arlington Partners LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 25.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,680 shares of the company’s stock after purchasing an additional 5,334 shares during the period. Johnson & Johnson accounts for 1.7% of Arlington Partners LLC’s portfolio, making the stock its 22nd biggest position. Arlington Partners LLC’s holdings in Johnson & Johnson were worth $4,324,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. &PARTNERS increased its holdings in shares of Johnson & Johnson by 51.5% in the 1st quarter. &PARTNERS now owns 31,942 shares of the company’s stock worth $5,050,000 after acquiring an additional 10,856 shares during the period. Douglas Lane & Associates LLC grew its position in Johnson & Johnson by 4.7% in the 1st quarter. Douglas Lane & Associates LLC now owns 545,254 shares of the company’s stock valued at $86,254,000 after buying an additional 24,686 shares in the last quarter. International Assets Investment Management LLC grew its position in Johnson & Johnson by 17.1% in the 1st quarter. International Assets Investment Management LLC now owns 15,614 shares of the company’s stock valued at $2,464,000 after buying an additional 2,277 shares in the last quarter. Salem Investment Counselors Inc. grew its position in Johnson & Johnson by 2.3% in the 1st quarter. Salem Investment Counselors Inc. now owns 178,529 shares of the company’s stock valued at $28,242,000 after buying an additional 4,050 shares in the last quarter. Finally, Cooper Financial Group grew its position in Johnson & Johnson by 1.3% in the 1st quarter. Cooper Financial Group now owns 9,682 shares of the company’s stock valued at $1,532,000 after buying an additional 126 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on JNJ shares. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. TD Cowen reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. The Goldman Sachs Group reduced their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Stock Down 1.3 %

Shares of NYSE JNJ traded down $2.16 during mid-day trading on Monday, reaching $162.96. The company had a trading volume of 1,547,674 shares, compared to its average volume of 7,002,637. The stock has a fifty day moving average of $162.98 and a two-hundred day moving average of $154.69. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market capitalization of $392.19 billion, a price-to-earnings ratio of 10.21, a PEG ratio of 2.65 and a beta of 0.52. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.66 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.04%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.